David M. Nanus
#153,149
Most Influential Person Now
David M. Nanus's AcademicInfluence.com Rankings
David M. Nanusphilosophy Degrees
Philosophy
#8547
World Rank
#11954
Historical Rank
Logic
#5576
World Rank
#6985
Historical Rank
Download Badge
Philosophy
David M. Nanus's Degrees
- Bachelors Biology Cornell University
Similar Degrees You Can Earn
Why Is David M. Nanus Influential?
(Suggest an Edit or Addition)David M. Nanus's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (2458)
- Renal-cell carcinoma. (1996) (1240)
- Divergent clonal evolution of castration resistant neuroendocrine prostate cancer (2016) (1032)
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) (889)
- Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. (2011) (706)
- Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. (2005) (442)
- Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. (2013) (405)
- Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. (2011) (401)
- Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (383)
- Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. (2010) (356)
- Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. (2007) (349)
- Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer (2013) (305)
- Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. (2004) (299)
- Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression (1998) (279)
- Interleukin‐10 production by human carcinoma cell lines and its relationship to interleukin‐6 expression (1993) (268)
- Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. (2015) (256)
- Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. (1996) (252)
- Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. (2000) (250)
- Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. (2003) (244)
- Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. (2007) (237)
- Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. (1989) (229)
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study (2019) (227)
- Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. (2013) (215)
- Androgen receptor splice variants determine taxane sensitivity in prostate cancer. (2012) (213)
- Clonal evolution of chemotherapy-resistant urothelial carcinoma (2016) (213)
- Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device (2012) (213)
- Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. (2007) (209)
- Patient derived organoids to model rare prostate cancer phenotypes (2018) (208)
- Challenges in recognizing treatment-related neuroendocrine prostate cancer. (2012) (183)
- Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma (2004) (180)
- High expression of the Met receptor in prostate cancer metastasis to bone. (2002) (176)
- Mutation and expression of the p53 gene in human malignant melanoma (1994) (175)
- Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. (1991) (172)
- Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. (2012) (169)
- Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. (2003) (155)
- Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. (1995) (155)
- Clinical features of neuroendocrine prostate cancer. (2019) (150)
- Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. (2000) (146)
- Aminopeptidase A is a functional target in angiogenic blood vessels. (2004) (145)
- Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. (2003) (143)
- Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. (1993) (138)
- A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers (2018) (133)
- Androgen receptor on the move: boarding the microtubule expressway to the nucleus. (2012) (132)
- Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? (2005) (131)
- Synaptic Activity Reduces Intraneuronal Aβ, Promotes APP Transport to Synapses, and Protects against Aβ-Related Synaptic Alterations (2009) (126)
- Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer (2010) (125)
- A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (123)
- Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity (2005) (121)
- A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 (2012) (116)
- Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling (2019) (115)
- Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach. (2004) (115)
- The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer (2015) (111)
- ERG induces taxane resistance in castration-resistant prostate cancer (2014) (107)
- Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. (2004) (105)
- Involvement of neutral endopeptidase in neoplastic progression. (2005) (102)
- Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study (2018) (101)
- Active chemotherapy for collecting duct carcinoma of the kidney (2002) (96)
- Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. (2011) (96)
- Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A. (1993) (95)
- Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. (2005) (92)
- Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma (2014) (91)
- Mutational analysis of the human p53 gene in malignant melanoma. (1991) (91)
- Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. (2020) (85)
- Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue (1997) (85)
- Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. (1990) (84)
- Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY (2018) (83)
- Retinoic Acid and the Histone Deacetylase Inhibitor Trichostatin A Inhibit the Proliferation of Human Renal Cell Carcinoma in a Xenograft Tumor Model (2005) (80)
- Methylation of the neutral endopeptidase gene promoter in human prostate cancers. (2000) (79)
- Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. (2001) (77)
- Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. (1996) (77)
- Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. (2002) (76)
- Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. (2006) (76)
- Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer (2019) (75)
- Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. (2016) (74)
- Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells (2006) (72)
- Identification and characterization of two androgen response regions in the human neutral endopeptidase gene (2000) (71)
- Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. (2016) (70)
- Infrequent point mutations of ras oncogenes in gastric cancers. (1990) (70)
- The role of HIF1α in renal cell carcinoma tumorigenesis (2014) (70)
- Neutral Endopeptidase Protein Expression and Prognosis in Localized Prostate Cancer (2004) (68)
- Infrequent ras oncogene point mutations in renal cell carcinoma. (1990) (65)
- Radiation‐induced angiosarcoma (1987) (65)
- Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. (2017) (65)
- Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer (2019) (63)
- Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. (2000) (63)
- A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. (1992) (63)
- Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). (2011) (60)
- Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. (2001) (59)
- Reduced levels of retinyl esters and vitamin A in human renal cancers. (2001) (58)
- Flow cytometry as a predictive indicator in patients with operable gastric cancer. (1989) (58)
- Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy (2011) (58)
- Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. (1992) (57)
- Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma. (1993) (54)
- Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase (2006) (53)
- Surveillance of urothelial carcinoma (2009) (53)
- Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. (1992) (53)
- The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. (2000) (52)
- Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. (1996) (50)
- Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential (2014) (49)
- Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. (2009) (47)
- Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. (2013) (46)
- Antibody-based therapeutics: Focus on prostate cancer (2005) (46)
- Neprilysin Inhibits Angiogenesis via Proteolysis of Fibroblast Growth Factor-2* (2006) (44)
- Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway. (2006) (43)
- Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C delta degradation. (2000) (43)
- Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma (2016) (43)
- The utility of monoclonal antibodies in the imaging of prostate cancer. (2002) (42)
- Isolation and characterization of circulating tumor cells in prostate cancer (2012) (42)
- Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells. (2007) (41)
- Of peptides and peptidases: the role of cell surface peptidases in cancer. (2003) (41)
- Up-Regulation of Retinoic Acid Receptor β Expression in Renal Cancers in Vivo Correlates with Response to 13-cis-Retinoic Acid and Interferon-α-2a (1999) (40)
- A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (2020) (40)
- α-Interferon Down-Regulates Epidermal Growth Factor Receptors on Renal Carcinoma Cells: Relation to Cellular Responsiveness to the Antiproliferative Action of α-Interferon (1991) (39)
- Phase 1/2 Clinical Trial of Interferon α2b and Weekly Liposome-encapsulated All-trans Retinoic Acid in Patients With Advanced Renal Cell Carcinoma (2007) (39)
- Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. (2009) (39)
- Chemotherapeutic strategies for renal cell carcinoma. (2003) (38)
- Direct Binding of Neutral Endopeptidase 24.11 to Ezrin/Radixin/Moesin (ERM) Proteins Competes with the Interaction of CD44 with ERM Proteins* (2004) (38)
- Circulating Tumor Cells from Prostate Cancer Patients Interact with E-Selectin under Physiologic Blood Flow (2013) (38)
- Clinical relevance of Neutral Endopeptidase (NEP/CD10) in melanoma (2007) (37)
- Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial (2005) (37)
- Advanced renal cell carcinoma (2020) (37)
- Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. (2017) (37)
- Bone biopsy protocol for advanced prostate cancer in the era of precision medicine (2018) (37)
- Gene microarray analysis of human renal cell carcinoma: The effects of HDAC inhibition and retinoid treatment (2008) (35)
- Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. (2007) (34)
- Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression (2006) (34)
- Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC) (2008) (34)
- Synergistic activation of the androgen receptor by bombesin and low-dose androgen. (2002) (33)
- Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. (2016) (32)
- Isochromosome 12p in non-seminoma cell lines: karyologic amplification of c-ki-ras2 without point-mutational activation. (1990) (32)
- Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. (2019) (31)
- Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma. (2006) (31)
- Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells (2008) (31)
- Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer (2020) (31)
- SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy (2020) (31)
- Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney. (2003) (30)
- Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas (2004) (30)
- Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer (2013) (29)
- Analyses of the Transcriptome and Metabolome Demonstrate That HIF1α Mediates Altered Tumor Metabolism in Clear Cell Renal Cell Carcinoma (2015) (29)
- Endothelin‐1 enhances the expression of the androgen receptor via activation of the c‐myc pathway in prostate cancer cells (2009) (29)
- Novel investigative approaches for advanced renal cell carcinoma. (2000) (28)
- Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a. (1999) (28)
- A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. (1992) (28)
- Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. (2006) (27)
- Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2. (2007) (27)
- Aminopeptidase A expression and enzymatic activity in primary human renal cancers. (1998) (25)
- Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies (2010) (24)
- Chemosensitization of Androgen-Independent Prostate Cancer with Neutral Endopeptidase (2004) (24)
- Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer (2005) (23)
- Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). (2010) (23)
- Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. (2020) (23)
- Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter (2006) (22)
- Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer (2021) (21)
- Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions. (1996) (21)
- Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome (2015) (21)
- ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features. (2016) (21)
- All‐trans retinoic acid (ATRA)‐induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL) (2019) (20)
- Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer. (2020) (20)
- Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma (2019) (20)
- Interaction of retinoic acid and interferon in renal cancer cell lines. (2000) (20)
- A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma (2004) (20)
- Phase I trial of interferon α2b and liposome‐encapsulated all‐trans retinoic acid in the treatment of patients with advanced renal cell carcinoma (2002) (20)
- Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer (2021) (20)
- Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. (2019) (19)
- Transformation of human kidney proximal tubule cells by a src-containing retrovirus. (1991) (19)
- Reduced Lecithin (2004) (19)
- Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer (2000) (18)
- Correction: Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device (2012) (18)
- The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E). (2018) (18)
- Reduced Lecithin:Retinol Acyltransferase Expression Correlates with Increased Pathologic Tumor Stage in Bladder Cancer (2004) (18)
- Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. (2007) (18)
- Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. (2016) (17)
- Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. (2011) (17)
- Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC). (2006) (16)
- Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer (2019) (16)
- Transformation of human kidney proximal tubule cells by ras-containing retroviruses. Implications for tumor progression (1989) (16)
- Lack of evidence of Ki‐ras codon 12 mutations in melanocytic lesions (1991) (16)
- Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis (2008) (15)
- Renal cell carcinoma. (1997) (14)
- Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth (2007) (14)
- Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed Consent. (2019) (14)
- Integrative Clinical Genomics of Advanced Prostate Cancer Graphical (2015) (14)
- Expression of the retinoblastoma gene product in renal tumors. (1996) (14)
- Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). (2020) (14)
- Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. (1992) (14)
- A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC) (2016) (13)
- Hematology and oncology clinical care during the coronavirus disease 2019 pandemic (2020) (13)
- Is methylation the key to CD10 loss? (2010) (13)
- Phase II trial of the anti-prostate specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 plus low-dose interleukin-2 (IL-2) in patients (pts) with recurrent prostate cancer (PC) (2007) (13)
- Expression and sequence analysis of the p21(WAF1/CIP1) gene in renal cancers. (1997) (13)
- Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC). (2021) (13)
- Immunologics and Chemotherapeutics for Renal Cell Carcinoma (2014) (13)
- Common germline-somatic variant interactions in advanced urothelial cancer (2020) (12)
- Chemotherapy for non-clear-cell renal cell carcinoma. (2006) (12)
- CD38 in Advanced Prostate Cancers (2021) (12)
- Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide (2021) (12)
- Abstract 5130: Prostate circulating tumor cells metastasize to bone via E-selectin expressed on endothelial cells. (2013) (12)
- Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients (2019) (12)
- Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. (2003) (12)
- Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer (2021) (11)
- alpha-Interferon down-regulates epidermal growth factor receptors on renal carcinoma cells: relation to cellular responsiveness to the antiproliferative action of alpha-interferon. (1991) (11)
- Retinoid receptor mRNA expression profiles in human bladder cancer specimens. (2005) (11)
- A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. (2008) (11)
- Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). (2018) (11)
- Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). (2012) (10)
- Maintenance sunitinib postchemotherapy (CT) in patients (pts) with advanced urothelial carcinoma (UC): A randomized placebo controlled phase II trial. (2016) (10)
- Phase 1/2 dose escalation trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer (CRPC) (2005) (10)
- Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series (2019) (10)
- Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC). (2014) (10)
- A Phase I Trial of Sorafenib Plus Gemcitabine and Capecitabine for Patients With Advanced Renal Cell Carcinoma: New York Cancer Consortium Trial NCI 6981 (2011) (10)
- Mutation and expression of the low affinity neurotrophin receptor in human malignant melanoma (1996) (10)
- Negative regulation of NEP expression by hypoxia (2013) (9)
- A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer. (2013) (9)
- Final results of 2-dose fractionation of 177Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). (2016) (9)
- Phase I dose-escalation study of docetaxel/predisone and fractionated 177Lu-J591 for metastatic castrate-resistant prostate cancer (metCRPC). (2010) (9)
- Anti-tumor effect of novel cationic biomaterials in prostate cancer. (2014) (9)
- The Tale of Two Hypoxia-Inducible Factors in Renal Cell Carcinoma. (2016) (8)
- Phase 2 trial of 177Lutetium (177Lu) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (177Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). (2008) (8)
- Using circulating tumor cells to advance precision medicine in prostate cancer. (2017) (8)
- A randomized phase II trial of 177lu radiolabeled monoclonal antibody J591 (177Lu-J591) and ketoconazole in patients (pts) with high-risk castrate biochemically relapsed prostate cancer (PC) after local therapy. (2010) (8)
- Phase II Study of Lutetium-177 – Labeled Anti-Prostate-Speci fi c Membrane Antigen Monoclonal Antibody J 591 for Metastatic Castration-Resistant Prostate Cancer (2013) (7)
- Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity (1988) (7)
- B‐Lymphoproliferative disorders: A Proposed unified pathogenetic pathway (2007) (7)
- Expression and sequence analysis of the SDI1/WAF1/CIP1/p21 tumor suppressor gene in prostate cancer cell lines. (1996) (7)
- Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. (2018) (7)
- Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy. (2019) (7)
- Kidney cancer: Novel targets in altered tumour metabolism in kidney cancer (2015) (7)
- Membrane metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin-releasing peptide on stem/progenitor cells (2019) (7)
- Renal Cell Carcinoma and Interferon at the Millennium (2001) (7)
- Detection of the p110 beta subunit of phosphatidylinositol 3-kinase complexed with neutral endopeptidase. (2002) (6)
- Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature (2009) (6)
- Neutral endopeptidase is a myristoylated protein (2010) (6)
- Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer (2021) (6)
- Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer (2012) (6)
- Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC). (2012) (6)
- Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma (2022) (6)
- Expression of the kidney-associated differentiation glycoprotein gp160 and resistance to the antitumor effects of interferon alpha in renal cell carcinomas. (1998) (6)
- TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC). (2013) (6)
- Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC) (2019) (6)
- NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma (2020) (6)
- 177Lu-J591 monoclonal antibody (Lu-J591) therapy in metastatic castrate-resistant prostate cancer (metCRPC): Correlation of antibody-tumor targeting and treatment response (2008) (5)
- A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC). (2004) (5)
- Increase in Prostate Cancer Metastases at Radical Prostatectomy in the United States. (2017) (5)
- AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer (2021) (5)
- TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2016) (5)
- Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC). (2015) (5)
- Precision medicine program for whole-exome sequencing (WES) provides new insight on platinum sensitivity in advanced prostate cancer (PCa). (2015) (5)
- Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC). (2020) (5)
- Clinical Outcome of Postoperative Adjuvant Immunochemotherapy with Sizofiran for Patients with Resectable Gastric Cancer: a Randomised Controlled Study (1991) (5)
- Retinoids and Prostate Cancer (2000) (5)
- Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. (2019) (5)
- NCI 6896: A phase I trial of suberoylanilide hydroxamic acid (SAHA) and 13-cis retinoic acid in the treatment of patients with advanced renal cell carcinoma (RCC). (2011) (5)
- Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. (2019) (5)
- Recent advances in the management of renal cell carcinoma (2016) (5)
- Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets. (2011) (4)
- Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC. (2015) (4)
- Differences in ambulatory care fragmentation between cancer survivors and noncancer controls (2020) (4)
- Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide. (2020) (4)
- Circulating tumor cell (CTC) enumeration in patients with metastatic neuroendocrine prostate cancer (NEPC) and castration-resistant prostate cancer (CRPC). (2014) (4)
- The role of HIF1α in renal cell carcinoma tumorigenesis (2014) (4)
- Cancer therapies that are gone with the Wnt (2015) (4)
- New treatment approaches for metastatic renal cell carcinoma (2000) (4)
- Defining a molecular subclass of treatment resistant prostate cancer. (2015) (4)
- The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy (2022) (4)
- Validation of a Circulating Tumor DNA‐Based Next‐Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing (2021) (4)
- Generating a neoantigen map of advanced urothelial carcinoma by whole exome sequencing. (2016) (4)
- PD16-11 COMPARISON OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED RADIONUCLIDE THERAPY (TRT) WITH LUTETIUM-177 ( 177 LU) VIA ANTIBODY J591 VS SMALL MOLECULE LIGAND PSMA-617 (2020) (4)
- Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage (2021) (3)
- Healthcare Fragmentation and Cardiovascular Risk Control Among Older Cancer Survivors in the REasons for Geographic and Racial differences in Stroke (REGARDS) Study (2020) (3)
- A randomized phase Ib/II study of nivolumab with or without BMS-986253 in combination with a short course of ADT in men with castration-sensitive prostate cancer (MAGIC-8). (2019) (3)
- Zr-J 591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (3)
- Final phase II results of NCI 6981: A phase I/II study of sorafenib (S) plus gemcitabine (GEM) and capecitabine (CAP) for advanced renal cell carcinoma (RCC). (2011) (3)
- Abstract 4865: Prognostic value of BRCA2 and AR gene alterations in advanced prostate cancer patients treated with PSMA-targeted radionuclide therapies (2019) (3)
- Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (2019) (3)
- MP50-19 DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY (177LU-J591) FOR MCRPC (2016) (3)
- Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). (2012) (3)
- Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC). (2012) (3)
- 952 ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)-BASED RADIOIMMUNOTHERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A DECADE OF EXPERIENCE WITH RADIOLABELED (RL)-J591 (2012) (3)
- Abstract 4081: Taxane sensitivity in prostate cancer is determined by androgen receptor splice variants. (2013) (3)
- Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). (2009) (3)
- Rovalpituzumab tesirine (Rova-T) as a therapeutic agent for Neuroendocrine Prostate Cancer (NEPC). (2017) (3)
- Modulation of 11beta-hydroxysteroid dehydrogenase expression by bombesin: a possible mechanism for glucocorticoid resistance in androgen independent prostate cancer. (2008) (3)
- Systemic chemotherapy in the management of bladder cancer. (1989) (3)
- Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR) (2022) (2)
- Mitochondrial Ndufa4l2 Enhances Deposition of Lipids and Expression of Ca9 in the TRACK Model of Early Clear Cell Renal Cell Carcinoma (2021) (2)
- Noninvasive measurement of prostate-specific membrane antigen (PSMA) expression with radiolabeled J591 imaging: A prognostic tool for metastatic castration-resistant prostate cancer (CRPC). (2013) (2)
- Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2014) (2)
- Tumor and Stem Cell Biology Activation of HIF 2 a in Kidney Proximal Tubule Cells Causes Abnormal Glycogen Deposition but not Tumorigenesis (2013) (2)
- Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC) (2007) (2)
- Antiprostate-specific membrane antigen (PSMA)-based radioimmunotherapy: A combined analysis of radiolabeled-J591 studies. (2011) (2)
- Association of CTCAE v4 grading of hypertension with toxicity in patients with renal cancer receiving vascular endothelial growth factor (VEGF)-targeting agents. (2013) (2)
- Rational redesign of neutral endopeptidase binding to merlin and moesin proteins (2009) (2)
- Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591. (2015) (2)
- Reversal of the low-affinity neurotrophin receptor stromal-epithelial expression pattern between benign and malignant human prostate. (1998) (2)
- Prospective analysis of prostate cancer (PC) circulating tumor cells (CTCs) to predict response to docetaxel (DOC) chemotherapy. (2012) (2)
- Abstract 1947: Rovalpituzumab tesirine as a therapeutic agent for neuroendocrine prostate cancer (2018) (2)
- 2-weekly versus 3-weekly docetaxel for prostate cancer. (2013) (2)
- Highly portable quantitative screening test for prostate-specific antigen at point of care (2021) (2)
- PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma. (2016) (2)
- In vitro method to observe E-selectin-mediated interactions between prostate circulating tumor cells derived from patients and human endothelial cells. (2014) (2)
- Sorafenib (S) plus gemcitabine (GEM) and capecitabine (CAP) for advanced renal cell carcinoma (RCC): Updated phase I results from a phase I/II trial (NCI 6981) (2008) (2)
- Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT). (2019) (2)
- Cancer and cardiovascular-related perceived risk in a diverse cancer center catchment area (2022) (2)
- Pharmacokinetics (PK), safety and tolerability of atrasentan (ABT-627, ATN) in combination with docetaxel (DOC) in men with hormone refractory prostate cancer (HRPC). (2006) (2)
- Phase 2 trial of 177Lutetium (177Lu) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (177Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC) (2006) (2)
- Prospective analysis of prostate cancer (PC) circulating tumor cells (CTCs) to predict response to docetaxel (DOC) chemotherapy. (2012) (2)
- Faculty Opinions recommendation of Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. (2016) (2)
- Preliminary results of a phase I study: A chimeric monoclonal anti IL-6 antibody CNTO 328 in combination with docetaxel in patients with hormone refractory prostate cancer (2007) (2)
- Baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY. (2015) (2)
- Neuroendocrine prostate cancer (NEPC) after androgen deprivation therapy (ADT): Clinical characteristics. (2012) (2)
- Value of serum neuroendocrine markers in evaluation of neuroendocrine prostate cancer: A validation study using metastatic biopsies. (2019) (2)
- Abstract LB-59: ERG induces taxane resistance in castration-resistant prostate cancer. (2013) (2)
- Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC). (2022) (1)
- Radioimmunotherapy of Prostate Carcinoma (2013) (1)
- Abstract 4696: Non-invasive measurement of prostate-specific membrane antigen (PSMA) expression with radiolabeled J591 imaging: a promising biomarker for PSMA-based radioimmunotherapy. (2013) (1)
- Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC). (2017) (1)
- Upper tract urothelial carcinoma is non-basal and T-cell depleted. (2018) (1)
- Radiolabeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for nonmetastatic castration-resistant prostate cancer (CRPC): A randomized phase II trial. (2011) (1)
- Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC). (2012) (1)
- Original Articles TARGETING METASTATIC PROSTATE CANCER WITH RADIOLABELED MONOCLONAL ANTIBODY J591 TO THE EXTRACELLULAR DOMAIN OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (2003) (1)
- Whole exome sequencing to reveal chemotherapy-driven evolution of platinum-resistant metastatic urothelial cancer. (2015) (1)
- Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 immunotherapy for prostate cancer (2016) (1)
- Perioperative chemotherapy treatment patterns in stage III transitional cell carcinoma (TCC) (1998-2003): A report from the National Cancer Data Base (NCDB). (2006) (1)
- Abstract 6511: Androgen receptor (AR) genomic alterations and clinical outcome with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (2020) (1)
- 1237: Surveillance of Transitional Cell Carcinoma: Stage Migration and Survival Trends, 1993-2003 (2006) (1)
- Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count. (2021) (1)
- Abstract CT143: Results of combined targeting of prostate-specific membrane antigen (PSMA) with alpha-radiolabeled antibody 225Ac-J591 and beta-radiolabeled ligand 177Lu-PSMA I&T: preclinical and initial phase 1 clinical data in patients with metastatic castration-resistant prostate cancer (mCRPC) (2022) (1)
- Abstract 4745: Precision cancer medicine program for whole-exome sequencing of metastatic tumors reveals biomarkers of response (2015) (1)
- 600P Final results of phase I/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC) (2021) (1)
- Molecular cloning of the human kidney differentiation antigen gpl60: Human aminopeptidase A (2005) (1)
- Abstract CT413: Lutetium-177-labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic non-prostate solid tumors (2014) (1)
- Neutrophil-to-lymphocyte ratio as a prognostic biomarker for overall survival in men with advanced prostate cancer treated with platinum chemotherapy. (2019) (1)
- Abstract A33: Utilizing insulin the treatment of prostate cancer with BKM120 abrogates the therapeutic effect of PI3K pathway inhibition (2015) (1)
- Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets. (2011) (1)
- Abstract 748: Phase I trial of fractionated-dose177Lutetium radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) in patients with metastatic castration-resistant prostate cancer (metCRPC) (2012) (1)
- Cell cycLe inhibitiON to target the EVolution of urOthelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients. (2020) (1)
- A Phase I/II Study for Analytic Validation of Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (1)
- Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival? (2016) (1)
- Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC). (2014) (1)
- A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). (2021) (1)
- Eliciting the Social Determinants of Cancer Prevention and Control in the Catchment of an Urban Cancer Center. (2021) (1)
- AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY. (2020) (1)
- Serial ctDNA tracking reveals clonal evolution dynamics in advanced urothelial carcinoma (UC). (2019) (1)
- Abstract 134: Immunogenomic landscape of neuroendocrine prostate cancer (NEPC) (2019) (1)
- Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents. (2013) (1)
- Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers. (2013) (1)
- Immunogenomic landscape of neuroendocrine prostate cancer (NEPC). (2019) (1)
- Abstract 646: Liquid biopsy transcriptomics identify pathways associated with poor outcomes and immune phenotypes in men with mCRPC (2022) (1)
- Radiolabeled J591 Antibody Delivers Lethal Hit to Advanced Prostate Cancers in a Phase I Trial (2004) (1)
- 744 Outcomes of pre-operative chemotherapy in bladder cancer patients including node-positive disease (2015) (0)
- Faculty Opinions recommendation of Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. (2011) (0)
- Proteines de fusion endopeptidase/anticorps anti-psma servant au traitement du cancer (2002) (0)
- Faculty Opinions recommendation of Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. (2008) (0)
- Evidence-based therapy of non-clear-cell and sarcomatoid renal cell carcinoma (2011) (0)
- Patient derived organoids to model rare prostate cancer phenotypes (2018) (0)
- Abstract 957: Aurora kinase and N-myc are involved in neuroendocrine differentiation of prostate cancer and are new drug targets (2011) (0)
- Targeted next-generation sequencing (NGS) of advanced prostate cancer (PCA) using formalin-fixed tissue. (2012) (0)
- Abstract 3880: Next generation sequencing for discovery of somatic mutations and clonal relationships in platinum-resistant metastatic urothelial cancer (2015) (0)
- Phase I/II trial of interferon {alpha}2b and ATRA-IV in the treatment of patients with advanced renal cancer (2005) (0)
- Use of a navigable interface for integrated whole genome and transcriptome sequencing as a platform for pursuit of therapeutic targets in advanced prostate cancers. (2023) (0)
- Malignant Melanoma : Markers of Transformation Induction of Growth Factor RNA Expression in Human Updated (2006) (0)
- 2563 Screening and baseline analysis of circulating tumor cell (CTC) counts and androgen receptor (AR) localization with clinical characteristics of men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY (2015) (0)
- Fractionated dose radiolabeled anti−prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu−J591) for progressive metastatic castration−resistant prostate cancer (mCRPC). (2016) (0)
- Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT). (2021) (0)
- Abstract LB-486: Overexpression of a mutated, constitutively active HIF2α promotes the carcinogenesis of TRACK mouse (2012) (0)
- Development of a Radiolabeled Monoclonal Antibody to Prostate-Specific Membrane Antigen (2005) (0)
- The genomic landscape of metastatic clear cell renal cell carcinoma (ccRCC) after treatment with systemic therapy. (2019) (0)
- Phase II randomized controlled trial (RCT) of medical intensive nutrition therapy (MINT) to improve chemotherapy (CT) tolerability in malnourished patients with solid tumor malignancies. (2020) (0)
- Analysis of genomic alterations in matched circulating tumor cell DNA (CTC DNA) and plasma tumor DNA (ctDNA) in men with metastatic castration resistant prostate cancer (mCRPC). (2018) (0)
- Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC). (2021) (0)
- Serial ctDNA evaluation to predict clinical progression in patients with advanced urothelial carcinoma. (2022) (0)
- PO-33 Hemostatic activation and fibrinolysis with prostate cancer before and after hormonal therapy (2021) (0)
- Abstract 923: Analysis of microtubule perturbations and androgen receptor localization in circulating tumor cells from castration resistant prostate cancer patients as predictive biomarkers of clinical response to docetaxel chemotherapy (2014) (0)
- CONTINUING MEDICAL EDUCATION BRADY UROLOGY GRAND ROUNDS CONFERENCES (2006) (0)
- Detection of germline deleterious mutations in prostate cancer patients with use of a validated 30-gene sequencing assay. (2018) (0)
- 380: Decreased Expression of the Human Stem Cell Marker, REX-1 (ZFP-42), in Renal Cell Carcinoma (2006) (0)
- Neuroendocrine prostate cancer (NEPC) after androgen deprivation therapy (ADT): Clinical characteristics. (2012) (0)
- AR nuclear localization and microtubule bundling as markers of docetaxel and cabazitaxel sensitivity in metastatic castration-resistant prostate cancer (mCRPC): Prospective biomarker analysis from TAXYNERGY. (2017) (0)
- Abstract 426: Variant allele frequency changes and treatment responses in advanced prostate cancer (2018) (0)
- Radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer (CRPC). (2011) (0)
- Fatalistic cancer beliefs and self-reported cancer screening behaviors among diverse urban residents (2022) (0)
- Abstract 451: Transferrin Receptor identifies a distinct pool of circulating tumor cells from metastatic prostate cancer patients with unique molecular profiles enriched in AR variants (2019) (0)
- Recent advances in the management of renal cell carcinoma [version 1; referees: 3 approved] (2016) (0)
- Abstract LB-018: Defining a molecular subclass of treatment-resistant prostate cancer (2015) (0)
- Faculty Opinions recommendation of Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. (2016) (0)
- Abstract 3412: Quadruple immunofluorescence protocol for identification of the metastatic potential of prostate CTCs (2012) (0)
- Recent advances in management of renal cancer (2009) (0)
- Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial. (2022) (0)
- Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
- A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA. (2023) (0)
- Abstract CT014: Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer (2023) (0)
- Abstract 4971: Quantitative image analysis of androgen receptor (AR) and tubulin biomarker profiles in circulating tumor cells (CTCs) from metastatic castration resistant prostate cancer (mCRPC) patients (2016) (0)
- Abstract C22: Massively parallel DNA-sequencing of aggressive prostate cancer reveals disease heterogeneity and identifies targetable mutations (2012) (0)
- Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue. (2012) (0)
- Abstract 2736: A digital droplet PCR assay for the quantitation of androgen receptor and splice variant expression in CTCs from metastatic castration resistant prostate cancer patients (2017) (0)
- Award Number: W81XWH-04-1-0056 TITLE: Comparative Analysis of Vitamin A (Retinol) Regulated Genes in African-American and Caucasian Prostate Cancer Patients (2007) (0)
- Next generation RNA sequencing of neuroendocrine prostate cancer. (2010) (0)
- Clinical relevance of neutral endopeptidase overexpression in melanoma. (2006) (0)
- Cancer cell assays by use of immunocapture, subcellular imaging, and programmed cell release in gedi microdevices (2010) (0)
- Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage (2021) (0)
- Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential (2014) (0)
- Resource Integrative Clinical Genomics of Advanced Prostate Cancer (2016) (0)
- SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based chemotherapy (PLT). (2019) (0)
- Prostate Cancer Clinical Consortium Clinical Research Site: Targeted Therapies (2015) (0)
- High efficiency capture of circulating tumor cells from patient blood using geometrically-enhanced differential immunocapture (2009) (0)
- FUNCTIONAL ASSAYS OF DRUG-TARGET ENGAGEMENT ON CIRCULATING TUMOR CELLS CAPTURED FROM PATIENT BLOOD CORRELATE WITH PATIENT PROGRESSION (2011) (0)
- Effect of androgen deprivation therapy combined with nivolumab on the systemic antitumor immune response in castration-sensitive prostate cancer. (2020) (0)
- Anti-Angiogenic Action of Neutral Endopeptidase (2006) (0)
- First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer. (2023) (0)
- Phase II Trial of Suramin in Patients with Advanced Renal Cell Carcinoma : Treatment Results , Pharmacokinetics , and Tumor Growth Factor Expression 1 (2006) (0)
- Multi-gene hereditary cancer testing, family history and prognosis in men with prostate cancer. (2019) (0)
- Faculty Opinions recommendation of Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. (2012) (0)
- NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma (2023) (0)
- Elevated markers of hemostasis, fibrinolysis and angiogenesis in patients with advanced prostate cancer decrease following hormonal therapy in responding patients (2012) (0)
- Abstract 296: Characterization of prostate cancer circulating tumor cells using E-selectin coated-microtubes (2011) (0)
- Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue. (2012) (0)
- Analyses of the transcriptome and metabolome to elucidate the role of HIF1{alpha} in clear cell renal cell carcinoma metabolism. (2015) (0)
- 608: Neutral Endopeptidase Targeted to Prostate Cancer Cells Via Fusion with an Anti-Prostate Specific Membrane Antigen Monoclonal Antffiody (2004) (0)
- Faculty Opinions recommendation of Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. (2009) (0)
- Prognostic impact of clinical and pathologic criteria in neuroendocrine and aggressive variant prostate cancer. (2016) (0)
- Circulating tumor DNA (ctDNA) to detect neuroendocrine prostate cancer genomic and DNA methylation changes. (2020) (0)
- Circulating tumour cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis (2019) (0)
- Abstract CT140: Pilot study of “hyperfractionated” anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC) (2016) (0)
- Increased utilization of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (PSMA-TRT) in African American (AA) patients at an academic medical center. (2023) (0)
- Abstract 1749: Stability of copy-number profiles defines two molecular subtypes during urothelial carcinoma’s evolution (2017) (0)
- The antitumor activity of taxanes in prostate cancer is mediated through inhibition of AR nuclear accumulation and androgen-dependent signaling (2008) (0)
- Nearly All Cancer Survivors Return to Primary Care (2022) (0)
- Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC). (2022) (0)
- Abstract 3492: Using CTCs to interrogate mechanisms of taxane resistance in the prospective TAXYNERGY clinical trial in prostate cancer. (2013) (0)
- Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591. (2023) (0)
- Abstract B193: PD-L1 somatic alterations predict sensitivity of advanced prostate cancer patients to platinum-based chemotherapy (2019) (0)
- Randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC). (2023) (0)
- Clonal heterogeneity in platinum-resistant metastatic urothelial cancer. (2015) (0)
- Risk of venous thromboembolism, survival, and expression of procoagulant genes in neuroendocrine versus castration-resistant prostate cancer. (2018) (0)
- Abstract 2857: Expression of mutated, constitutively active HIF1α in the mouse kidney results in early stage clear cell renal cell carcinoma (2011) (0)
- Abstract 4891: Molecular and functional analysis of circulating tumor cells in castrate resistant prostate cancer using a geometrically enhanced microfluidic device based on PSMA immunocapture (2011) (0)
- Randomized trial of five or two MRI-guided adaptive radiotherapy treatments for prostate cancer (FORT). (2023) (0)
- Abstract CT310: Molecular correlates of activity and survival in a phase I/II trial of sorafenib plus gemcitabine and capecitabine for advanced renal cell carcinoma (2014) (0)
- Abstract CT097: Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) (2019) (0)
- Prostate Cancer National Summit's Call to Action. (2019) (0)
- MP46-10 UTILIZING INSULIN IN THE TREATMENT OF PROSTATE CANCER WITH BKM120 ABROGATES THE THERAPEUTIC EFFECT OF PI3K PATHWAY INHIBITION (2015) (0)
- MP29-10 PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) RECEIVING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED RADIONUCLIDE THERAPY (TRT) (2023) (0)
- Abstract 1145: Analysis of circulating tumor cells from castrate resistant prostate cancer patients captured via a microfluidic device using the prostate specific membrane antigen antibody (2010) (0)
- Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer. (2022) (0)
- Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC. (2022) (0)
- Abstract 3634: Molecular determinants of taxane activity using CTCs from CRPC patients (2012) (0)
- Minton, Denise R. and Fu, Leiping and Mongan, Nigel P. and Shevchuk, Maria M. and Nanus, David M. and Gudas, Lorraine J. (2016) Role of NADH Dehydrogenase (Ubiquinone) 1 alpha subcomplex 4-like (2017) (0)
- Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy. (2021) (0)
- Abstract CT304: Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 plus low-dose interleukin-2 (IL-2) in patients with recurrent prostate cancer (PC) (2014) (0)
- Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC). (2021) (0)
- PSMA-positive circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic castrate resistant prostate cancer. (2023) (0)
- Genomic instability is enriched in localized prostate cancers from men of African ancestry. (2022) (0)
- A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. (2021) (0)
- Comparative Analysis of Vitamin A (Retinol) Regulated Genes in African-American and Caucasian Prostate Cancer Patients (2007) (0)
- Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling (2019) (0)
- Abstract NG06: Genomic dissection of the clonal evolution dynamics of chemotherapy-resistant urothelial carcinoma (2017) (0)
- Phase II Trial of Suramin in Patients with Advanced Renal Cell Carcinoma: Treatment Results, Pharmacokinetics, and Tumor Growth Factor Expression1 (2006) (0)
- PD11-08 A 30-GENE HEREDITARY CANCER MUTATION ANALYSIS PREDICTS TIME TO BIOCHEMICAL RECURRENCE IN CLINICALLY LOCALIZED PROSTATE CANCER (2019) (0)
- Preoperative radiotherapy for high-risk prostate cancer (PORT-PC) trial. (2019) (0)
- Faculty Opinions recommendation of Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. (2016) (0)
- Serial circulating tumor DNA (ctDNA) measurement to predict progression in patients (pts) with advanced urothelial carcinoma (aUC). (2020) (0)
- Increased risk of venous thromboembolism (VTE) and shorter survival in neuroendocrine versus castration-resistant prostate cancer (2018) (0)
- Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC). (2020) (0)
- Abstract CT306: Radiolabeled anti-PSMA antibody J591 immunotherapy is associated with favorable circulating tumor cell (CTC) count control in men with castration-resistant prostate cancer (2015) (0)
- Title: Liquid-biopsy transcriptomic profiling uncovers molecular mediators of resistance to androgen receptor signaling inhibition in lethal prostate cancer Authors: (2021) (0)
- 149: Lentiviral Vector Neutral Endopeptidase Gene Transfer Suppresses Prostate Cancer Tumor Growth (2007) (0)
- Punctuated evolution of copy-number alterations to define two molecular subtypes of muscle-invasive urothelial carcinoma. (2017) (0)
- Editorial: Molecular genetics and therapeutic advances in renal carcinoma (2023) (0)
- 837TiPPhase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) (2017) (0)
- Capture and analysis of prostate cancer circulating tumor cells (CTCS) using geometrically enhanced differential immunocapture (GEDI). (2011) (0)
- Abstract CT122: Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC) (2020) (0)
- MP24-05 LONG-TERM FOLLOW-UP AND PROGNOSTIC FACTOR ANALYSIS IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO RECEIVE PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED LUTETIUM-177 (177LU) (2021) (0)
- A randomized mCRPC phase 2b study of the BET bromodomain inhibitor (BETi) zen-3694 and enzalutamide vesus enzalutamide. (2022) (0)
- Phase I trial of a histone deacetylase inhibitor (HDACI) and retinoid acid (RA) in patients (pts) with advanced solid tumor malignancies. (2006) (0)
- Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC). (2012) (0)
- Circulating tumor cell release by use of novel immunocapture chemistry in gedi microdevices (2011) (0)
- Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC). (2020) (0)
- Orthotopic model of renal cell carcinoma. (2001) (0)
- Targeted radioimmunotherapy (RIT) with 177Lutetium labeled J591, anti-prostate-specific membrane antigen (PSMA) monoclonal antibody: Initial results of a phase 2 trial in patients with metastatic androgen-independent prostate cancer (AIPC) (2007) (0)
- Outcomes of preoperative chemotherapy in bladder cancer patients including node-positive disease. (2015) (0)
- Integrated whole exome and RNA sequencing to reveal distinct genomic and transcriptomic landscape of upper tract urothelial carcinoma. (2016) (0)
- 760: Expression of TNF-Related Apoptosis Inducing Ligand (TRAIL) is Reduced in Bladder Tumor Tissue but may be Restored in Bladder Cancer Cell Lines by Treatment with Retinoic Acid (2005) (0)
- Abstract 1264: CTC-based biomarker analysis and correlation with clinical response to PSMA-TRT in mCRPC (2022) (0)
- Effect of prostate-specific membrane antigen (PSMA) radioimmunotherapy on circulating tumor cell (CTC) count. (2015) (0)
- Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC). (2014) (0)
- Abstract 3971: Non-invasive assessment of prostate-specific membrane antigen (PSMA) expression as a prognostic marker in men with metastatic castration-resistant prostate cancer (mCRPC) (2016) (0)
- OC-15 Hemostatic activation, fibrinolysis and angiogenesis are increased in patients with advanced prostate cancer (PC) and decrease in response to hormonal therapy (2010) (0)
- Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype (2014) (0)
- Somatic alterations in a seven-gene DDR gene panel predicts platinum sensitivity in advanced prostate cancer patients. (2019) (0)
- Estramustine Plus a Taxane for Advanced Prostate Cancer: The New Standard Therapy? (2002) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David M. Nanus?
David M. Nanus is affiliated with the following schools:
